November 15, 2026 · Phase 3 readout
CGON Phase 3 readout: a positive outcome, +14.0%
On November 15, 2026, Cretostimogene Grenadenorepvec — CG Oncology, Inc. (High-Risk Non-Muscle-Invasive Bladder Cancer) reached its Phase 3 readout. The result was a positive outcome, and the stock moved +14.0% in the window around the event. It had already run +24.3% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.
The move
$74.40
1d before
$84.78
Event day
$84.78
1d after
$84.78
5d after
Our prediction vs. the result
CatalystAlert called this one neutral (+3.8% expected); the stock actually moved +14.0%. Model confidence at the time: 48%.
See the full scored track recordPre-catalyst setup
+24.3%
30-day run-up
7573%
30-day volatility
2.8×
volume spike
